Table 2.

Multivariate analysis of factors affecting progression-free survival (PFS).

p	95% CI	HR			Variables
0.185	0.97–1.16	1.06			Age *
0.963	0.55–1.76	0.99	≥25 vs. <25		BMI
<0.001	2.11–8.21	4.16	B vs. A		Luminal subtype
0.874	0.61–1.78	1.04	Yes vs. No		Visceral disease
0.470	0.42–1.49	0.79	≤14 vs. >14		G8 score
0.077	0.93–3.83	1.89	2 vs. 0–1		ECOG PS
0.267	0.32–1.36	0.67	Fulvestrant vs. AI		Type of hormone therapy
0.255	0.74–3.07	1.51	vs. Palbociclib	Ribociclib	Type of CDK4/6inh
0.918	0.50–1.85	0.97		Abemaciclib

* Considered as continuous variable.